The Tetanus vaccine is a critical immunization tool designed to prevent tetanus, a potentially severe and life-threatening bacterial infection caused by Clostridium tetani. Tetanus bacteria are commonly found in soil, dust, and manure, entering the body through wounds or cuts. Vaccination against tetanus is typically administered as part of the combination vaccine DTaP (Diphtheria, Tetanus, and acellular Pertussis) for children or Tdap/Td (Tetanus, Diphtheria, and Pertussis/ Tetanus and Diphtheria) for adolescents and adults. The vaccine stimulates the immune system to produce antibodies that neutralize the toxins produced by the tetanus bacteria. Booster doses are recommended every ten years to maintain immunity, as tetanus spores are widespread in the environment. Prompt medical attention, wound care, and vaccination are essential components of tetanus prevention. The Tetanus vaccine has been instrumental in reducing the incidence of tetanus globally, emphasizing the importance of routine immunization in preventing this serious and potentially fatal disease. Ongoing research focuses on vaccine safety, efficacy, and strategies to improve global vaccine coverage.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States